申请人:Zeneca Limited
公开号:US05880130A1
公开(公告)日:1999-03-09
The invention concerns pyrimidine derivatives of formula wherein m is 1, 2 or 3; each R.sup.1 is independently hydrogen, hydroxy, (un)substituted amino, nitro, halogeno, cyano, carboxy, (un)substituted carbamoyl, ureido, (1-4C) alkoxycarbonyl, (un)substituted (1-4C)alkyl, (un)substituted (1-4C)alkoxy, (1-3C)alkylenedioxy, (1-4C)alkylthio, (1-4C)alkylsulphinyl, (1-4C)alkyl-sulphonyl, (2-4C)alkanoyloxy; n is 1, 2 or 3; and each R.sup.2 is independently hydrogen, hydroxy, halogeno, trifluoromethyl, trifluoromethoxy, amino, nitro, cyano, (1-4C)alkyl, (1-4C)alkoxy, (1-4C)alkylamino, di-\x9b(1-4C)alkyl!amino, (1-4C)alkylthio, (1-4C)alkylsulphinyl, (1-4C)alkylsulphonyl, (2-4C)alkanoylamino, (2-4C)alkanoyl or (1-3C)alkylenedioxy; or a pharmaceutically-acceptable salt thereof; processes for their preparation; pharmaceutical compositions containing them; and the use of the receptor tyrosine kinase inhibitory properties of the compounds in the treatment of cell-proliferation diseases.
该发明涉及以下结构的嘧啶衍生物,其中m为1、2或3;每个R.sup.1独立地为氢、羟基、(未)取代的氨基、硝基、卤素、氰基、羧基、(未)取代的氨甲酰基、脲基、(1-4C)烷氧羰基、(未)取代的(1-4C)烷基、(未)取代的(1-4C)烷氧基、(1-3C)烷二氧基、(1-4C)烷基硫氧基、(1-4C)烷基砜基、(1-4C)烷基磺酰基、(2-4C)烷酰氧基;n为1、2或3;每个R.sup.2独立地为氢、羟基、卤素、三氟甲基、三氟甲氧基、氨基、硝基、氰基、(1-4C)烷基、(1-4C)烷氧基、(1-4C)烷基氨基、二-(1-4C)烷基氨基、(1-4C)烷基硫氧基、(1-4C)烷基砜基、(1-4C)烷基磺酰基、(2-4C)烷酰胺基、(2-4C)烷酰基或(1-3C)烷二氧基;或其药学上可接受的盐;它们的制备方法;含有它们的药物组合物;以及利用这些化合物的受体酪氨酸激酶抑制性能治疗细胞增殖性疾病。